Short answer
Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Aardvark Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Business updates issued August 11, 2026
- Full results and operational details furnished in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 results: $14.4M net loss, or $0.66 per share, unchanged from Q2 2025
- Cash, equivalents and short-term investments totaled $73.9M, supporting projected operations into late 2027
- ARD-101’s Phase 3 HERO and OLE trials were terminated after an FDA full clinical hold
- Unblinded HERO and OLE data assessment expected in Q3 2026 to determine PWS program next steps
- R&D fell to $10.5M from $13.1M as trial activity paused, while G&A rose to $4.6M from $2.7M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aardvark Therapeutics, Inc. 8-K filings
Get the next AARD 8-K as it lands
Follow AARD for push alerts, or ask the research agent what this filing means.